Repligen Corporation (RGEN) ist ein börsennotiertes Unternehmen im Gesundheitswesen Sektor, tätig in der Medical - Instruments & Supplies Branche. Der Hauptsitz des Unternehmens ist in Waltham, MA, United States. Der aktuelle CEO ist Olivier Loeillot.
RGEN hat IPO-Datum 1986-04-29, 1,778 Vollzeitbeschäftigte, gelistet an der NASDAQ Global Select, eine Marktkapitalisierung von $7.38B.
Repligen Corporation is a global bioprocessing technology company that develops and commercializes systems and products for biological drug manufacturing. The company serves biopharmaceutical, life sciences, and diagnostics customers across North America, Europe, and Asia Pacific with a comprehensive portfolio including Protein A affinity chromatography resins, pre-packed chromatography columns, cell culture growth factors, filtration systems, and process analytics solutions. Its product lines—such as OPUS chromatography columns, XCell filtration systems, and SoloVPE spectroscopy platforms—support critical stages of biologic drug purification, concentration, and quality control. Repligen was founded in 1981 and is headquartered in Waltham, Massachusetts.
